The Review on Antimicrobial Resistance (AMR), was commissioned in July 2014 by the UK Prime Minister, who asked economist Jim O’Neill to analyse the global problem of rising drug resistance and propose concrete actions to tackle it internationally. The Review on AMR was jointly supported by the UK Government and Wellcome Trust, although operated with full independence from both. Established as a two-year, time-limited process, the Review engaged widely with international stakeholders to understand and propose solutions to the problem of drug-resistant infections from an economic and social perspective, and produced its final report and recommendations in the summer of 2016.
Lord Jim O’Neill, chairman of the independent Review on Antimicrobial Resistance, which has assisted in the development of the Declaration, said: “This Declaration from industry is a major step forward in establishing a properly global response to the challenges of drug resistance. I am really impressed that such a wide range of companies have been able to agree on a common set of principles and commitments across these important issues: this is a level of consensus that we have not previously seen from the industry on this topic.”
AMR is one of the most serious public health threats globally with infections cause by multidrug-resistant bacteria currently estimated to kill 25,000 people every year in Europe alone.
The Review on Antimicrobial Resistance has now completed its work. The content of this website is frozen as an archive of the Review’s work, and will not be updated further. The legacy of the Review will be maintained by its sponsor organisations, the Wellcome Trust and the UK Department of Health.
For queries about the legacy of the Review, or for media enquiries for the Review’s former chair, Jim O’Neill only, please contact email@example.com.